Wells Fargo lowered the firm’s price target on Varonis (VRNS) to $46 from $48 and keeps an Equal Weight rating on the shares. Shares of Varonis traded down after market close on mixed Q4 results. While the SaaS transition is accelerating, the impact from GenAI remains small and ARR growth is decelerating to just 15% in CY25, which does not yet warrant a premium valuation.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRNS: